Inflammatory bowel disease (IBD) is a chronic, relapsing, tissue-destructive disease caused by immunological, environmental, and genetic factors. Current treatment of colitis reduces periods of active disease and helps maintain periods of remission but produces marginal results; thus, the disease becomes refractory. Resveratrol, a naturally occurring polyphenol, has displayed promising activity in treating chronic inflammatory and autoimmune diseases. In this issue, Singh et al. investigate the use of resveratrol in the treatment of experimental colitis in mice. Resveratrol attenuated the symptoms of colitis and the cellular infiltrate in colon tissue and decreased the expression of cyclooxygenase-2 and activation of nuclear factor-κB. Interestingly, Singh et al. found that resveratrol may reverse the effects of colitis through the up-regulation of silent mating type information regulation-1 (SIRT1) expression. This study demonstrates the potential role of SIRT1 in experimental colitis and suggests that SIRT1 may be a novel therapeutic target for colitis.
See article at J Pharmacol Exp Ther 2010, 332:829–839.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics